Programmatic introduction of the new and re-purposed anti-tuberculosis medicines for treatment of drug-resistant tuberculosis

Course content

  • Epidemiology of TB, MDR-TB, XDR-TB and TB/HIV; social determinants
  • Perspectives of the National Tuberculosis Programs on implementing innovative diagnostics and treatment for M/XDRTB
  • Laboratory diagnosis of TB and TB drug resistance; TB diagnostic algorithm proposed by the European TB Laboratory Initiative (ELI)
  • Programmatic approach to the treatment of rifampicin-resistant TB 
  • Clinical issues in new drug introduction, regimen design, and drug-drug interactions; off-label use of new TB drugs; use in special populations
  • Organisation of TB care in outpatient settings
  • Role of patient-centred care, support and adherence-support package
  • Adjuvant therapies; the role of surgery using new and re-purposed drugs
  • Drug safety; scope of safety data collection and definitions; active drug safety monitoring and management (aDSM)
  • Clinical management of adverse events
  • Monitoring and evaluation requirements for the use of new and re-purposed drugs
  • Pharmacokinetic and minimum inhibitory concentration (MIC) variability as determinants of TB clinical outcomes in adults and children - state of the evidence.

Site visits to MDR-TB department, National TB Reference Laboratory and TB Outpatient department. 

REGISTRATION AND INFORMATION

Target audience:

Clinicians, staff of the national TB programs, responsible for diagnostics and treatment of DR-TB, from countries with high level DR-TB

Duration and language:

5 business days (from Monday to Friday). Currently course is available in

Training fee:

1200 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa support

Additional costs:

hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced per diem


 .